What this article helps you consider
- Separate the unopened and in use periods
- Translate the intended use into a study design
- Include product age in the assessment
Separate the unopened and in use periods
An expiry date for a sealed container and a period after first opening answer different questions. The same distinction applies to a dry product before and after reconstitution. Do not assume that the unopened shelf life continues unchanged once the product’s physical state or exposure has changed.
EMA’s in-use stability guidance addresses susceptible medicinal products in multidose containers. Its quality questions and answers provide additional context, including solid oral products and other relevant situations. Nutraceutical liquids and powders need an independently defined category and market assessment, although the experimental principle remains useful. R36R37
Translate the intended use into a study design
Define opening frequency, withdrawal quantity, dispensing device, storage conditions and the proposed duration of use. Include the preparation steps described in the intended instructions. Reconstitution introduces questions about diluent quantity, mixing, final volume, pH and the quality of water or other permitted diluent.
A realistic simulation follows a controlled schedule that represents normal handling. It should not quietly assume that the user transfers the product into a sterile laboratory vessel or closes a bottle more carefully than the supplied closure allows. Document every assumption so that the study’s relevance can be judged.
Include product age in the assessment
A fresh product may tolerate repeated opening better than one near the end of its unopened shelf life. Consider ageing when selecting study material, especially where preservative content, antioxidant capacity or physical structure changes during storage. The established EMA guidance includes testing of an aged batch as part of its pharmaceutical approach. R36
The illustration distinguishes product age before opening from elapsed time after opening. Both dimensions can matter. Testing a new batch for a short period does not automatically establish the behaviour of a nearly expired bottle used for the full proposed period.
Product age and time in use are separate dimensions
A newly prepared product starts its own period after opening or reconstitution.
Conceptual explanation. No product result, acceptance criterion or universal regulatory sequence is established by this illustration.
Measure quality and delivered dose
Select chemical, physical, microbiological and dispensing measurements according to the risks. For a suspension, redispersibility and dose uniformity after the labelled shaking procedure may be central. For drops, assess whether the supplied device consistently delivers the intended amount across the bottle’s use. Precipitation or evaporation can change concentration even when the total amount of active ingredient remains unchanged.
Microbial evaluation should address the relevant specification and preservation strategy. A preservative challenge and an in-use simulation serve different purposes. Neither should be presented as an automatic replacement for the other. Sterile products require a separate, appropriately controlled approach to microbial and container-related questions.
Examine the final remaining product
The last portion of a multidose container can experience the greatest cumulative exposure and the largest headspace. Plan sampling so that it provides information about the material remaining at the end of the intended use. Avoid removing so much for intermediate analysis that the study no longer resembles the proposed fill and withdrawal pattern.
Consider a hypothetical reconstituted powder that forms sediment after several days. Determine whether the labelled mixing procedure restores acceptable distribution and whether the delivered portions remain consistent. A satisfactory assay of a completely homogenised laboratory composite would not settle that use-related question.
Use the findings to establish a justified period after opening or reconstitution, associated storage conditions and any handling instructions. Assess whether the pack allows the user to identify the opening date where necessary. The product information should express a conclusion supported by the actual study rather than use a convenient standard period for every formulation.
Stabicon can help develop use simulations and analytical plans that assess the product as it is handled, providing a stronger basis for multidose and reconstitution instructions.
References & further reading
Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.
- R36EMA In Use Stability Testing of Human Medicinal Products
CPMP/QWP/2934/99, 2001. Defined pharmaceutical scope for susceptible multidose products.
- R37EMA Quality of Medicines Questions and Answers Part Two
Living quality-information page. Includes in-use stability considerations.
- R01ICH Q1A R2 Stability Testing of New Drug Substances and Products
Final guideline, 2003. Pharmaceutical scope; apply target-authority requirements.
From insight to a defined programme
Bring your next technical question.
Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.
Discuss this topic with Stabicon






